Connection
Wesley Nuffer to Hypoglycemic Agents
This is a "connection" page, showing publications Wesley Nuffer has written about Hypoglycemic Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.075 |
|
|
|
-
Trujillo JM, Nuffer WA. Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes. Pharmacotherapy. 2017 Apr; 37(4):481-491.
Score: 0.270
-
Trujillo JM, Nuffer W. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents. Pharmacotherapy. 2014 Nov; 34(11):1174-86.
Score: 0.230
-
Nuffer W, Trujillo JM, Ellis SL. Technosphere insulin (Afrezza): a new, inhaled prandial insulin. Ann Pharmacother. 2015 Jan; 49(1):99-106.
Score: 0.229
-
Trujillo JM, Nuffer W. Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes. Ann Pharmacother. 2014 Nov; 48(11):1494-501.
Score: 0.227
-
Trujillo JM, Wettergreen SA, Nuffer WA, Ellis SL, McDermott MT. Cardiovascular Outcomes of New Medications for Type 2 Diabetes. Diabetes Technol Ther. 2016 12; 18(12):749-758.
Score: 0.066
-
Ryan M, Megyeri S, Nuffer W, Trujillo JM. The potential role of GLP-1 receptor agonists in osteoarthritis. Pharmacotherapy. 2025 Mar; 45(3):177-186.
Score: 0.029
-
Tall Bull S, Nuffer W, Trujillo JM. Tirzepatide: A novel, first-in-class, dual GIP/GLP-1 receptor agonist. J Diabetes Complications. 2022 12; 36(12):108332.
Score: 0.025